Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer

  • Received : 2011.10.25
  • Accepted : 2011.11.02
  • Published : 2012.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes associated with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclinical studies. But their precise mechanism of action has not been elucidated. In this study, a novel synthetic inhibitor of HDAC, 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide [IN-2001] was examined for its antitumor activity and the underlying molecular mechanisms of any such activity on human breast cancer cell lines. IN-2001 effectively inhibited cellular HDAC activity ($IC_{50}$ = 0.585 nM) inMDA-MB-231 human breast cancer cells. IN-2001 caused a significant dose-dependent inhibition of cell proliferation in estrogen receptor (ER) negative MDA-MB-231human breast cancer cells. Cell cycle analysis revealed that the growth inhibitory effects of IN-2001 might be attributed to cell cycle arrest at $G_0/G_1$ and/or $G_2$/Mphase and subsequent apoptosis in human breast cancer cells. These events are accompanied by modulating several cell cycle and apoptosis regulatory genes such as CDK inhibitors $p21^{WAF1}$ and $p27^{KIP1}$ cyclin D1, and other tumor suppressor genes such as cyclin D2. Collectively, IN-2001 inhibited cell proliferation and induced apoptosis in human breast cancer cells and these findings may provide new therapeutic approaches, combination of antiestrogen together with a HDAC inhibitor, in the hormonal therapy-resistant ER-negative breast cancers. In summary, our data suggest that this histone deacetylase inhibitor, IN-2001, is a novel promising therapeutic agent with potent antitumor effects against human breast cancers.

Keywords

References

  1. Archer. S. Y., Meng. S., Shei. A. and Hodin. R. A. (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95, 6791-6796. https://doi.org/10.1073/pnas.95.12.6791
  2. Banwell, C. M., Singh, R., Stewart, P. M., Uskokovic, M. R. and Campbell, M. J. (2003) Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 164, 83-98. https://doi.org/10.1007/978-3-642-55580-0_5
  3. Blobel, G. A. (2000) CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95, 745-755.
  4. Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E. and Fornace, A, J. Jr. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36, 343-350. https://doi.org/10.1038/ng1317
  5. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon- Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A. and Richon, V. M. (2000a) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170.
  6. Butler, L. M., Higgins, B., Fox, W. D., Agus, D. B., Cordon-Cardo, C. and Scher, H. J. (2000b) Hybrid polar inhibitors of histone deacetylase suppress the growth of the CWR22 human prostate cancer xenograft. Proc. Am. Assoc. Cancer Res. 41, 289.
  7. Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T. R., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon-Cardo, C., Scher, H. I., Breslow, R., Richon, V. M., Rifkind, R. A. and Marks, P. A. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962-970.
  8. Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. and La Thangue, N. B. (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3, 667-674. https://doi.org/10.1038/35083062
  9. Cress, W. D. and Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184, 1-16. https://doi.org/10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
  10. David, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A. and Dejean, A. (1998) Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16, 2549-2556. https://doi.org/10.1038/sj.onc.1202043
  11. Davis, T., Kennedy, C., Chiew, Y. E., Clarke, C. L. and deFazio, A. (2000) Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 6, 4334-4342.
  12. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. and van Kuilenburg, A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749. https://doi.org/10.1042/BJ20021321
  13. Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K. and Benz, C. C. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528. https://doi.org/10.1146/annurev.pharmtox.45.120403.095825
  14. Finnin, M. S., Donigian, J. R. and Pavletich, N. P. (2001) Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 8, 621-625. https://doi.org/10.1038/89668
  15. Finzer, P., Kuntzen, C., Soto, U., zur Hausen, H. and Rosl, F. (2001) Inhibitors of histone deacetylasearrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20, 4768-4776. https://doi.org/10.1038/sj.onc.1204652
  16. Fournel, M., Trachy-Bourget, M. C., Yan, P. T., Kalita, A., Bonfi ls, C., Beaulieu, C., Frechette, S., Leit, S., Abou-Khalil, E., Woo, S. H., Delorme, D., MacLeod, A. R., Besterman, J. M. and Li, Z. (2002) Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 62, 4325-4330.
  17. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M. and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98, 87-92. https://doi.org/10.1073/pnas.98.1.87
  18. Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G. and Davidsen,S. K. (2003) Gene expression profi ling of multiple histone deacetylase (HDAC) inhibitors: defi ning a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163. https://doi.org/10.4161/cbt.2.2.349
  19. Gottlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G. and Heinzel, T. (2001) Valproicacid defi nes a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978. https://doi.org/10.1093/emboj/20.24.6969
  20. Gray, S. G. and Ekström, T. J. (2001) The human histone deacetylase family. Exp. Cell Res. 262, 75-83. https://doi.org/10.1006/excr.2000.5080
  21. Grunstein, M. (1997) Histone acetylation in chromatin structure and transcription. Nature 389, 349-352. https://doi.org/10.1038/38664
  22. Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M. and Marks, P. A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101, 1241-1246. https://doi.org/10.1073/pnas.0307708100
  23. Johnstone, R. W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug. Discov. 1, 287-299. https://doi.org/10.1038/nrd772
  24. Johnstone, R. W. and Licht, J.D. (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18. https://doi.org/10.1016/S1535-6108(03)00165-X
  25. Kouzarides, T. (2000) Acetylation: a regulatory modifi cation to rival phosphorylation? EMBO J. 19, 1176-1179. https://doi.org/10.1093/emboj/19.6.1176
  26. Kramer, O. H., Göttlicher, M. and Heinzel, T. (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12, 294-300. https://doi.org/10.1016/S1043-2760(01)00438-6
  27. Marks, P.A., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. and Kelly, W.K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202. https://doi.org/10.1038/35106079
  28. Qui, L., Kelso, M. J., Hansen, C., West, M. L., Fairlie, D. P. and Parson, P. G. (1999) Anti-tumouractivity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80, 1252-1258. https://doi.org/10.1038/sj.bjc.6690493
  29. Reynisdóttir, I., Polyak, K., Iavarone, A. and Massague, J. (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9, 1831-1845. https://doi.org/10.1101/gad.9.15.1831
  30. Richon, V. M., Sandhoff, T. W., Rifkind, R. A. and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014-10019. https://doi.org/10.1073/pnas.180316197
  31. Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B. and Grant, S. (2001) Evidence of a functional role forthe cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. 19, 181-191.
  32. Roth, S. Y., Denu, J. M. and Allis, C. D. (2001) Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120. https://doi.org/10.1146/annurev.biochem.70.1.81
  33. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599-606. https://doi.org/10.1101/gad.12.5.599
  34. Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I. and Coombes, R. C. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7, 971-976.
  35. Vigushin, D. M. and Coombes, R. C. (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13, 1-13. https://doi.org/10.1097/00001813-200201000-00001
  36. Villar-Garea, A. and Esteller, M. (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 112, 171-178. https://doi.org/10.1002/ijc.20372

Cited by

  1. A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1 vol.23, pp.5, 2015, https://doi.org/10.4062/biomolther.2015.026
  2. Effect of PVP formulation on the in vitro photodynamic efficiency of a photosensitizing phthalocyanine vol.23, pp.11, 2012, https://doi.org/10.1142/s108842461950189x